secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERUS CORP (CERS)
CIK:        0001020214
Form:       8-K
Filed at:   2021-08-03T23:59:59+00:00
Accession:  0001193125-21-234936
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cerus Q2 revenue $37.8M (+41% YoY); raises FY product revenue guidance to $118-122M
--------------------------------------------------------------------------------

- Total revenue $37.8M (+41% YoY); product revenue $31.5M (+46%) led by 128% North America platelet growth.
- FY2021 product revenue guidance raised to $118-122M from $110-114M, representing 28-33% growth over 2020.
- Net loss $15.4M ($0.09/sh) vs $14.9M ($0.09) in Q2 2020; cash and investments $122.8M at quarter end.
- Submitted PMA supplement for 7-day INTERCEPT platelet storage; final CE Mark module for INTERCEPT red cells.
- CMS granted NTAP for INTERCEPT Fibrinogen Complex; initial hospital contracts signed; LifeSouth collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1020214/000119312521234936/0001193125-21-234936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1020214/000119312521234936/d199644d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-234936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer